Stories
AstraZeneca Strikes 1.5 Billion Dollar AI Deal for Liver and Heart Drugs
- •AstraZeneca has partnered with artificial intelligence biotech firm insitro in a deal worth up to 1.5 billion dollars to discover new treatments for liver and heart diseases.
- •The agreement includes an upfront payment of 40 million dollars, with insitro also eligible for potential milestone payments and future sales royalties.
- •The collaboration focuses on metabolic dysfunction-associated steatohepatitis and cardiomyopathies, which have historically lacked effective therapies.
- •Insitro will utilize its Virtual Human AI platform, combining lab-grown cell models and machine learning, to identify causal disease biology and advance drug targets.
- •AstraZeneca will be responsible for running and funding all future clinical trials for the discovered development candidates.
Key Questions Answered
AstraZeneca has partnered with insitro in a deal worth up to $1.5 billion. The agreement includes a $40 million upfront payment, up to approximately $1.46 billion in development and commercial milestones, and royalties on future sales.
The multi-year collaboration focuses on metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease, and cardiomyopathies, which are diseases affecting the heart muscle. These conditions have historically lacked effective therapies due to challenges in identifying their root biological drivers.
Insitro will use its 'Virtual Human' AI platform, combining lab-grown cell models and machine learning, to pinpoint causal disease biology and advance AstraZeneca-nominated targets from discovery to the development stage. AstraZeneca will then fund and run the subsequent clinical trials.
